Zoetis stock is trading -33.18% below its average target price of $221.7 after dropping -3.3% during today's morning session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $187.0 to $260.0 per share.
Zoetis's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 0.8%. The stock's short ratio is 0.94. The company's insiders own 0.23% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 95.7%. In conclusion, we believe there is positive market sentiment regarding Zoetis.
Institutions Invested in Zoetis
Date Reported | Holder | Percentage | Shares | Value |
---|---|---|---|---|
2023-12-31 | Vanguard Group Inc | 9% | 40,334,966 | $5,974,818,710 |
2023-12-31 | Blackrock Inc. | 8% | 36,493,861 | $5,405,835,808 |
2023-12-31 | State Street Corporation | 4% | 19,322,219 | $2,862,200,394 |
2023-12-31 | State Farm Mutual Automobile Insurance Co | 4% | 16,344,542 | $2,421,117,086 |
2023-12-31 | Capital International Investors | 3% | 14,676,576 | $2,174,041,274 |
2023-12-31 | Price (T.Rowe) Associates Inc | 3% | 13,716,681 | $2,031,852,023 |
2023-12-31 | Bank of America Corporation | 3% | 13,505,953 | $2,000,636,883 |
2023-12-31 | Alliancebernstein L.P. | 3% | 12,573,450 | $1,862,505,209 |
2023-12-31 | Morgan Stanley | 3% | 12,318,748 | $1,824,776,201 |
2023-12-31 | Geode Capital Management, LLC | 2% | 9,844,613 | $1,458,282,571 |